Sofronievska, Maja and Petrovska, Tanja and Radulovska, Jasminka and Tahir, Senol and Arsov, Stefan (2024) COVID‑19’s effects on symptoms associated with benign prostatic hyperplasia. Discover Public Health.
Text (Naslovna na zurnal)
Home _ Discover Public Health.PDF Download (407kB) |
|
Text (Ureduvacki odbor)
Editorial board _ Discover Public Health.pdf Download (470kB) |
|
Text (Celosen trud)
s12982-024-00206-w.pdf Download (602kB) |
|
Text (SCIMAGO rank)
Emerging Themes in Epidemiology.PDF Download (882kB) |
Abstract
Purpose The objective of this study was to identify the relationship between COVID-19 and lower urinary tract symptoms
in patients with benign prostatic hyperplasia.
Materials and methods Data from forty outpatients who had recovered from COVID-19 and had previously been diagnosed with and treated medically for benign prostatic hyperplasia were assessed. Pre- and post-COVID-19 assessments
were also conducted for prostate volume, total serum PSA concentration, and lower urinary tract symptoms. Hospitalizations related to COVID-19, the time interval between COVID-19 recovery and urologist referrals, and comorbidities
were considered. Independent Student’s t-tests or chi-square tests were used to compare changes in all variables. For
the Spearman rank correlation analysis, only variables with a univariate analysis of p<0.10 were included in the multiple
regression models, with the signifcance threshold set at two-tailed p<0.05.
Results After COVID-19, there was an increase in IPSS (12.87±3.76), total serum PSA (1.56±0.87), and prostate volume
(10.68±11.73). Multiple linear regression analysis of the independent predictors of IPSS increase revealed pre-COVID-19
IPSS with intermittency and straining as leading symptoms and bladder catheterization during COVID-19. Pre-COVID-19
frequency and nocturia status were found to be independent predictors of increased blood volume, hospital treatment
for COVID-19, and bladder catheterization. A weak stream, UTI, and hypertension were found to be independent predictors of a PSA increase. The time from COVID-19 recovery to urologist referral was shorter in patients with post-COVID-19
IPSS increase (p<0.05).
Conclusion Determining the predictors of the efects of COVID-19 on worsening BPH symptoms is essential for continued
monitoring and treatment.
Item Type: | Article |
---|---|
Impact Factor Value: | 3.6 |
Subjects: | Medical and Health Sciences > Clinical medicine Medical and Health Sciences > Health sciences |
Divisions: | Faculty of Medical Science |
Depositing User: | Maja Sofronievska |
Date Deposited: | 23 Sep 2024 11:46 |
Last Modified: | 23 Sep 2024 11:46 |
URI: | https://eprints.ugd.edu.mk/id/eprint/34679 |
Actions (login required)
View Item |